The Role of Atrial Natriuretic Peptide T Left Ventricular Function and Electrolyte Homeostasis in Congestive Heart Failure Patients

KEYWORDS

Congestive heart failure, ANP, Left ventricular ejection fraction

Fadhila Shahwan Al-Doski
Department of medical Physiology, College of Medicine. University of Mosul, Iraq

Abdul-Aziz Ahmed Aziz
Department of medical Physiology, College of Medicine. University of Mosul, Iraq

Jasim M. T. Al-Hayali
Department of Medicine, Cardiac Care Unit, College of Medicine. University of Mosul, Iraq

ABSTRACT

Atrial natriuretic peptides (ANP) attract great attention in the last years. This interest is due to the fact that natriuretic peptides plays an important role on body fluids and electrolytes balance and on blood pressure homeostasis under normal physiological conditions as well as in a variety of cardiovascular diseases (CVDs), especially congestive heart failure.

The present study was conducted on 100 subjects (50 patients with congestive heart failure (CHF) who admitted to the Coronary Care Unit, Medical wards and Echocardiography Unit at Ibn-Sena teaching hospital, Mosul, Iraq, from 1st October 2003 to 30th September 2004, and also (50) apparently healthy volunteers as control group included in this study. The biochemical parameters were measured in plasma which include the concentrations of sodium (PNa), potassium (PK), creatinine (PCr), urea (PUr), osmolality (POsm), and ANP. The concentration of other parameters were also measured in urine including sodium (UNa), potassium (UK), osmolality (UOsm) and creatinine (UCr). Using plasma and urine values, calculation of creatinine clearance (CCR) and fractional excretion of sodium (FENa) were done. Echocardiographic assessment of left ventricular ejection fraction (LVEF) was also done.

In conclusion, plasma level of ANP was significantly elevated in patients with CHF and it could be considered as an important diagnostic and prognostic indicators especially in patients with CHF. A considerable degree of disturbance in body fluids and electrolytes balance together with significant reduction in renal function also occur in patients with CHF. The study further accentuates the essential role of ANP in the defense mechanisms against body fluids and electrolytes disorders in different CVDs including congestive heart failure patients.

Introduction and Review of Literature:

The normal heart secretes atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP), the predominant members of a family of at least three structurally and functionally related hormones, they counteract cardiac over load by exerting a wide variety of effects on body fluids natriuresis, other electrolytes homeostasis and cardiovascular function

Both hormones (ANP) and (BNP) have diuretic, natriuretic and antihypertensive effects by inhibiting the renin-angiotensin-aldosterone system (RAAS), they have renal sympathetic activity. The hypotensive effect of these peptides is mediated primarily by a decrease in cardiac output brought by a reduction in intravascular volume.

Atrial natriuretic peptide is a potent vasodilator contributes in homeostatic regulation of body water, sodium, potassium and fat to lower blood pressure. The concept of congestive heart failure (CHF) comprises both the primary distortion of blood flow and pressure which characterized cardiac impairment and secondary disturbance of electrolytes and water metabolism with subsequent activation of neuro-humoral systems. Hyponatremia in (CHF) patients is usually hypovolemic and it cause retention of water, the patient becomes edematous, which is further enhanced by a diuretic therapy especially in patients with impaired renal function. Other studies considered hyponatremia as poor prognostic marker in patients with (CHF).

Hyponatremia and hypokalemia are the most frequent electrolytes disorders encountered in (CHF). The kidney is the main organ involved during the course of (CHF), the increase in renal blood flow will lead to decrease glomuler filtration rate (GFR), increase in tubular reabsorption of sodium and water with subsequent reduction of urine volume and urinary sodium excretion. The difference in (GFR) in patients with (CHF) with different cardiac index of (1.5-2), and less than 1.5ml/min/1.73m² was reflected by the concentration of plasma urea (P尿) and plasma creatinine (PCr).

Congestive heart failure is a neuroendocrine disorder both in relation to diagnosis and prognosis, it is found in experimental heart failure rats that (ANP) levels was 6.4 folds higher than that in normal rats. A marked increase of (ANP) plasma level was found in (CHF) patients with others with a positive correlation between (ANP) level and increased left and right atrial pressure.

The left ventricular ejection fraction (LVEF) is the most widely used index of cardiac function which is important diagnostic, therapeutic and prognostic indicator of (CHF). Low ejection fraction was inversely correlated with marked increase in (ANP) in patients with (CHF), and was negatively associated with increased risk of hospitalization and death.

This study was conducted in attempt to evaluate the role of plasma (ANP) level in maintaining body fluids and electrolyte balance in the face of various pathophysiological mechanisms encountered during the course of (CHF), and to study the correlation of this novel (ANP) hormone as a possible biochemical indicator of the cardiac dysfunction with other indices of the left ventricular function like (LVEF%).

Subjects Materials and Methods:

After recording the routine information, concerning name, age, address, body weight, height and consent for every participant in the study a careful history and physical examination was performed, they were asked about any past history of diabetes mellitus, ischemic heart disease and onset of the present illness. A general physical examination with special emphasis on reporting pulse rate, arterial blood pressure and the finding of heart auscultation.

This study was conducted on (100) subjects (50) patients with congestive heart failure (CHF), their age range between (25-70) years, their body weight was (52-100) kg, and height
was (152-180) cm. The classification system that is most commonly used to quantify the degree of functional limitation imposed by heart failure based on the criteria of the New York Heart Association (NHA) (16). This system assigns patients to one of four functional classes depending on the degree of effort needed to elicit symptoms:

Class I: Symptoms of heart failure only at levels that would limit normal individual activities.

Class II: Symptoms of heart failure with ordinary exertion.

Class III: Symptoms of heart failure on less than ordinary exertion.

Class IV: Symptoms of heart failure at rest.

Depending on this classification the patients were divided into four groups:

Group A Class I: This group included (22) patients with (CHF) aged (32-75) year (55.18±10.89), their body weight was (60-100)kg (74.90±10.48) and heights (152-180) cm. (166.90±7.81).

Group B class II: This group included (11) patients with (CHF) aged (25-79) years (55.27±12.86) with body weight of (52-93) kg (68.54±13.7) and heights (155-180) cm. (167.45±9.00).

Group C class III: This group included (8) patients with (CHF) aged (55-70)year (64.25±4.97) with body weights of (65-95) kg (73.25±10.26) and heights (154-180) cm. (168±9.0).

Group D class IV: This group included (9) patients with (CHF) aged (54-80)year (66,0 ± 8.58) with body weight (58-85) kg (68.88±8.65) and height (155-180)cm. (166.22±8.24).

The control group included (50) apparently healthy volunteers aged (24-67) year (45.76±9.77) their body weights (54-92)kg (71.34±10.53) and heights (145-186) cm. (167.6±9.73). All control subjects were scrutinized for the absence of any cardiac disease by thorough history and physical examination.

Chemical analysis:

1- Blood samples: 10 ml. of blood was collected from every participant from antecubital vein. The blood samples were placed in 2 separate tubes containing lithium heparin. The plasma samples were placed in 2 separate tubes containing lithium heparin. The plasma samples were kept in capped plastic tubes in the deep freeze (-20°C) until analysis.

F- Atrial natriuretic peptide (Pg/ml) (ANP)
E- Osmolality (mosm/Kg) (P Osm)
D- Concentration of urea (mmol/L) (P Ur)
C- Concentration of creatinine (mmol/L) (P Cr)
B- Concentration of potassium in the urine (mmol/L) (UK)
A- Concentration of sodium in the urine (mmol/L) (UNa)

2- Urine samples: Ten ml. of random urine samples were collected from patients and control groups. The urine samples were placed in capped plastic tubes and kept in deep freeze (-20°C) until analysis.

The following urinary parameters were determined:

A- Concentration of sodium in the urine (mmol/L)
B- Concentration of potassium in the urine (mmol/L)
C- Concentration of creatinine in the urine (mmol/L)
D- Urine osmolality (mosm/L)

Utilizing the urinary and plasma parameters together with age, body weight and height the following parameters were estimated:

a- Calculated creatinine clearance (C cr, ml/min/1.73m²). A simple formula has been used that allows the (C cr) to be predicted by estimation from (P cr) (16).

b- Fractional excretion of the filtered sodium (FE Na %) ,it measures the percent of filtered sodium in the urine by the following equation (17):

\[ \text{FE Na} = \left( \frac{\text{U Na} \times \text{P Cr}}{\text{P Na} \times \text{U Cr}} \right) \times 100 \]

Sodium and potassium concentrations were measured using an emission flame photometer (Corning 400, England). Plasma and urine creatinine were measured using a kit from BioSys following Kit procedure.

Plasma urea concentration was determined using a kit from Biobest (France). Plasma and urine osmolality were measured by freezing point depression technique using automated osmometer (Bibbysterilin, France).

Plasma atrial natriuretic peptide (ANP) level was determined by Enzyme Linked Immunosorbent Assay (ELIIZA) utilizing kits provided by DRG international Inc. USA.

Left Ventricular Ejection Fraction (LVEF) was determined by echocardiography: Tow dimension and M-mode echocardiogram was obtained for every subject participate in the study, ejection fraction was derived from two dimensional apical tw and four chamber views for volume measurement.

Statistical analysis:

1. Post hoc test was used to identify the differences in the mean of different parameters.
2. Studentnt-test (unpaired) was used.
3. Pearson correlation was performed to study the relationship between various parameters within each group.
4. All values were expressed as mean ± SD.

Results:

The mean ± SD of all studied parameters in patients with congestive heart failure (CHF) and the control group, and the level of significance between the two groups was shown in table (1):

There is a highly significant differences (P ≤ 0.00) between CHF and the control in the plasma concentration of sodium (P Na), osmolality (P Osm), creatinine (P Cr), urea (P U), atrial natriuretic peptide (ANP), and left ventricular ejection fraction (LVEF %).

Level (ANP) and left ventricular ejection fraction (LVEF %) . Also the urine concentration of sodium (P Na), FeNa , (U Osm) , (C cr) , and fraction excretion of sodium (FE Na %) show a highly significant differences (P ≤0.001) between the two studied groups . The plasma concentration of potassium (P K) was significantly different between the two groups at (P≤0.05). No significant differences was seen in the concentration on urine potassium (U K) and creatinine (U Cr) between both groups.

Table (1): Comparison of different parameters between (CHF) group and control group.

| Parameters | Group I (CHF) Mean ± S.D. | Control group Mean ± S.D. | P value |
|------------|---------------------------|---------------------------|---------|
| P Na mmol/L| 138.46 ± 3.48             | 140.67 ± 1.21             | <0.0001 |
There were significant positive correlations between PNa and both PNa and PK (r = 0.75, p<0.0001) respectively. It was also significantly higher in group A than that in group C and D (p<0.001) respectively. It was also significantly higher in group B than that in group D (p<0.05).

ii. There were significant differences in PNa between the four subgroups (F = 10.05, p< 0.0001). PNa was significantly higher in group II A than that in group C and D (p< 0.001 and p< 0.0001) respectively. It was also significantly higher in group B than in group D (p< 0.05).

iii. There were significant differences in PNa between the four subgroups (F = 9.92, p<0.0001). PNa was significantly higher in group A than that in group C and D (p< 0.005 and p<0.001) respectively.

iv. There were significant differences in PNa between the four subgroups (F=18.5, p<0.0001). PNa was significantly lower in group A than that in group B, C and D (p<0.0001). It was also significantly lower in group B than that in group D (p<0.05).

v. There were significant differences in PNa between the four subgroups (F = 14.1, p < 0.0001). It was significantly lower in group A than that in group B, C and D (p<0.005, p<0.0001 and p<0.0001) respectively. It was also significantly higher in group B than that in group C and D (p<0.01 and p<0.0001) respectively.

vi. There were significant differences in PNa between the four subgroups (F = 5.5, p < 0.002). UNa was significantly lower in group A than that in group B, C and D (p<0.05).

vii. There were significant differences in PNa between the four subgroups (F = 23.6, p<0.0001). UNa was significantly lower in group A than that in group B, C and D (p<0.001). It was also significantly lower in group B than that in group C (p<0.005).

viii. There were significant differences in PNa between the four subgroups (F = 27.5, p<0.0001). LVEF was significantly higher in group A than that in group B, C and D (p<0.001).

ix. There were significant differences in PNa between the four subgroups (F = 11.6, p<0.0001). UOsm was significantly higher in group A than that in group C and D (p<0.001).

x. There were significant differences in PNa between the four subgroups (F= 22.8, p < 0.0001). Plasma ANP was significantly lower in group A than that in group B, C and D (p<0.0001). It was also significantly higher in group B than in group D (p<0.001) and in group C than in group D (p<0.01).

xi. There were significant differences in PNa between the four subgroups (F= 27.5, p<0.0001). LVEF was significantly higher in group A than that in group B, C and D (p<0.0001).

\[ \text{Table (2): Correlation coefficient between different parameters within patients} \]

| Parameters          | ANP pg/ml | PNa mmol/l | PNa mmol/kg | PCr µmol/l | UPCR mmol/1.73m² | FE Na % | LVEF | P<0.05 |
|---------------------|-----------|------------|-------------|------------|------------------|--------|------|--------|
| ANP pg/ml           | NS        | NS         | NS          | -0.37      | NS                | NS     | -0.83|        |
| PNa mmol/l          | NS        | 0.41"      | 0.75"       | NS         | NS                | NS     | NS   |        |
| PNa mmol/kg         | NS        | 0.41"      | 0.34"       | NS         | NS                | NS     | NS   |        |
| PCr µmol/l          | NS        | NS         | NS          | NS         | NS                | NS     | NS   |        |
| UPCR mmol/1.73m²    | NS        | NS         | NS          | NS         | NS                | NS     | NS   |        |
| FE Na %             | NS        | NS         | NS          | NS         | NS                | NS     | NS   |        |

** Table (2): Correlation coefficient between different parameters within patients **

** NS : non-significant correlation. **
PO₄ mmol/L/kg 286.68 ± 8.06a 279.90 ± 7.56a 274.25 ± 7.88a 274.00 ± 4.60a
Pₘ₆ mmol/L 74.17 ± 4.63a 83.56 ± 7.03b 84.15 ± 4.63 89.76 ± 8.36
PU₇ mmol/L 4.25 ± 0.42b 4.56 ± 0.22 4.87 ± 0.19 4.98 ± 0.16
UN₈ mmol/L 121.73 ± 11.85 109.78 ± 11.52 95.11 ± 9.90 88.77 ± 7.41
UK mmol/L 68.73 ± 16.38b 56.63 ± 12.15 52.25 ± 16.37 47.66 ± 11.26
UO₉ mmsm/kg 684.13 ± 99.46a 571.4 ± 67.40 541.25 ± 74.62 520.44 ± 63.62
LVEF % 96.60 ± 7.86a 86.64 ± 5.83b 85.52 ± 4.13e 77.05 ± 2.77
FE % 0.87 ± 0.04a 0.78 ± 0.08 0.74 ± 0.06 0.72 ± 0.05
ANP pg/ml 76.04 ± 15.24a 93.00 ± 19.40d 131.14 ± 23.05 125.00 ± 26.65
LVEF % 43.09 ± 4.28a 35.90 ± 3.96b 30.87 ± 3.97 29.22 ± 5.91

The congestive heart failure patients (CHF) were divided into four groups (A, B, C, and D) according to the severity of the disease depending on the NHA classification (class one to four).

Fig (1): Show the mean plasma (ANP) concentration that was higher in group (D) it was (130 pg/ml) compared to other three groups, the lowest value of plasma (ANP) concentration was (72 pg/ml) seen in group (A) and differ significantly from respective values in groups (B, C and D). Plasma concentration of (ANP) in group (B) differ significantly from groups (C and D).

Fig (2): Show the mean values of creatinine clearance (Cr) in the four groups in group (A) was higher than its value in other three groups and differ significantly from group (B, C and D), while (Cr) in group (B) differ significantly from group (D). Creatinine clearance in group (C) also differ significantly from respective values in group B, C and D.

Fig (3): Show the mean values of left ventricular ejection fraction (LVEF%) in the four groups, its values in group (A) differ significantly from its respective values in groups (B, C and D). Also significant difference in (LVEF%).

Discussion:
A-Body fluids and electrolytes:
The mean plasma sodium (Pₙ₆) and urine sodium (Uₙ₆) in congestive heart failure (CHF) was lower than the control group. Twenty-eight percentage (28%) of studied patients showed hyponatremia while the remaining patients have normal levels of plasma sodium. Hyponatremia is common in (CHF) patients; this result from an inability of the kidney to excrete ingested water which is largely related to the associated fall in cardiac output and systemic blood pressure that stimulate secretion of the hypovolemic hormone renin[16]. With a subsequent increase in angiotensin II formation, ADH and norepinephrine[16,17].

The neurohumoral changes that are induced limit both sodium and water excretion in an attempt to return perfusion pressure to normal[20].

Potassium predominantly an intracellular cation, (23%) of patients with (CHF) had hypokalemia; dyshypokalemia had a serious dysfunction of the cardiac muscle and cardiac rhythm disorder with considerable morbidity and mortality. Potassium imbalance in (CHF) patients is largely due to alteration in urinary potassium excretion, all of the filtered potassium is reabsorbed in the proximal tubule and loop of Henle.

Urinary potassium is determined by potassium secretion from the cells of distal renal tubule and to less extent collecting ducts[17].

The mean plasma level of atrial natriuretic peptide (ANP) in patients with (CHF) is significantly higher than the control (P ≤ 0.0001), and as this hormone is a potent natriuretic pep-
Patients with (CHF) presented with low (U_{Na}) and fraction excretion of sodium (%FE_{Na}) lower than the control group (P≤0.0001), (14%) of the patients have hypoosmolality, they were either hyponatremic or had (P_{Na}) lower than patients with normal (P_{Na}).

B. The plasma creatinine, urea and creatinine clearance:

The mean creatinine clearance (C_{CR}) in patients with (CHF) was significantly lower than the control group (P≤0.0001), (14%) of the patients have hypoosmolality, they were either hyponatremic or had (P_{Na}) lower than patients with normal (P_{Na}).

The plasma level of urea was abnormally high in (16%) of the patients with (CHF), it is estimated at best that the clinical diagnosis is not so accurate in about (50%) of patients, accordingly an objective measurement of left ventricular function is essential for improving the accuracy of diagnosis (16). The mean value of (LVEF) in congestive heart failure patients was significantly lower than the control, negative correlation between the plasma level of (ANP) and (LVEF) was seen in (CHF) patients, therefore measurement of plasma (ANP) may be of value in determining the severity of congestive heart failure especially when the facility for performing of echocardiography is not available.

The level of urea was abnormally high in (16%) of the patients with (CHF), accordingly impaired GFR and tissue wasting observed during the course of the disease raises the possibility that increased urea production may be chiefly wasting observed during the course of the disease.

C. Atrial Natriuretic Peptide (ANP):

The mean plasma (ANP) in patients with (CHF) was significantly lower than that of the control and it was much higher in severe cases (group D) compared with milder cases (group A). Furthermore a significant negative correlation was found between plasma (ANP) and left ventricular ejection fraction in (CHF) patients, these results are consistent with the findings of other investigators (21, 22).

The plasma level of urea was abnormally high in (16%) of the patients with (CHF), it is estimated at best that the clinical diagnosis is not so accurate in about (50%) of patients, accordingly an objective measurement of left ventricular function is essential for improving the accuracy of diagnosis (16).

The mean value of (LVEF) in congestive heart failure patients was significantly lower than the control, negative correlation between the plasma level of (ANP) and (LVEF) was seen in (CHF) patients, therefore measurement of plasma (ANP) may be of value in determining the severity of congestive heart failure especially when the facility for performing of echocardiography is not available.

In conclusion, plasma levels of (ANP) was significantly elevated in patients with (CHF), patients with severe (CHF) tend to exhibit a higher level of (ANP) than mild cases. A negative correlation between (ANP) and (LVEF) was seen in (CHF) patients, this higher plasma (ANP) could be regarded as an important diagnostic and prognostic indicator of cardiac dysfunction in these patients. A significant negative correlation between (ANP) and creatinine clearance was also noted, a disturbance in body fluids, electrolyte balance together with reduction in renal function accentuates the inverse relationship between (ANP) and renal function, (ANP) has essential role in the defense mechanism against body fluids and electrolytes disorders in congestive heart failure patients.

REFERENCE

1. Ellis RL, David GG, Willis KS (1998). Natriuretic peptide. N Engl J Med. 339: 321-329.
2. Vanderheyden M, Bartunek J, Goethals M (2004). J Interv Card Electrophysiol; 9: 155-161.
3. Brandt RR, Wright RS, Redfield MM, Burnett JC Jr. (1993). Cardiac natriuretic peptides: gaining further insights into structure-function relationships. J Am Coll Cardiol; 54: 1033-1034.
4. Greenberg BD, (1996). Uremia in congestive heart failure. QJ Med;38 :117-133.
5. Chung BD, Bencen GH, Seilhamer JJ, Lowicki JA, Fiddes JC (1984). Nucleotide sequence of the gene encoding human atrial natriuretic factor precursor. Nature (London), 312: 656-658.
6. Cheng CI, Chen YH, Cha HT (2003). Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic cardiomyopathy. Cardiology, 100: 136-142.
7. Reyes AJ, Taylor SH (1999). Diuretics in cardiovascular therapy. The new clinic-pharmacological bases that matter. Cardiovasc Drugs Ther; 13: 371 - 398.
8. Kamel KS, Ehlerl JH, Richardson RM (1990). Uroine electrolytes and osmolality:When and how to use them. Am J Nephrol ; 10 : 89-102.
9. Hebert PC, Parr LL, Vittinghoff E, Pronovost PJ, Baker ER (2001). Ventricular long axis function is predictive of outcome in patients with chronic heart failure secondary to non-ischemic dilated cardiomyopathy Med Sci; 9: 566-565.
10. Luey A S, Bosch J P, Lewis J B, Evans E, Prieto MG, Smith W B, Shoemaker WC, Pickard C, Nakanishi J, Nishita S, Dolia P, Regnier H, DeBold MJ, Bresnihan B, PANG SC, Tse Y, Akermann (2000). ANP in regulation of arterial pressure and fluid–electrolyte balance: lessons from genetic mouse models. Genomics 3 : 45-58.
11. Greenberg BD, Bencen GH, Seilhamer JJ, Lowicki JA, Fiddes JC (1984). Nucleotide sequence of the gene encoding human atrial natriuretic factor precursor. Nature (London), 312: 656-658.
12. Ljungman S, Laragh JH, Cody RJ (1990) . Role of the kidney in congestive heart failure. Relationship in cardiac index to kidney function. Drug, 39: 103-121.
13. Ruskoaho H (2001). Cardiac hormones as diagnostic tools in heart failure. Endocrine Rev; 24: 341-355.
14. Randazzo MR, Sneep EY, Levet MA, Binder K (2003). Accuracy of emergency physician assessment of left ventricular ejection fraction and central venous pressure using echocardiography. Acad Emerg Med; 10 : 937 – 977.
15. Fans R, Henrey M, Oats AJ (2003). Ventricular long axis function is predictive of outcome in patients with chronic heart failure secondary to non-ischemic dilated cardiomyopathy Med Sci; 9: 566-565.
16. Cheng CI, Chen YH, Cha HT (2003). Risk stratification of in-hospital mortality in patients hospitalized for chronic congestive heart failure secondary to non-ischemic dilated cardiomyopathy Med Sci; 9: 566-565.
17. Ann Intern Med, 130 : 461-470.
18. Rosner M H (2004). Severe hyponatremia associated with use of thiazide diuretics and selective serotonin reuptake inhibitors. Am J Med; 116: 109-111.